It is my great honor to be invited as the editor of the book *Key Leaders' Opinion on Novel Progress in Diagnosis and Treatment of Bladder Cancer* and write the preface to this book. The introduction is presented as a themed collection of the related articles from journal of TAU recently published.

Bladder urothelial carcinoma (bladder cancer) is one of the most common malignant tumors of the human urinary system. With an increasing morbidity and mortality year by year, it has brought enormous social and economic burdens. The mechanism which cause occurrence and development of bladder cancer is complex, as well as it being impacted by numerous other complex risk factors, such as age, smoking status, environmental, and genetic factors. At the present, an early screening process for bladder cancer is not yet universally established. Most patients are not examined until clinical symptoms like hematuria occur; therefore, the disease often develops to the middle or late stage by this time, leading to a poor prognosis. Moreover, bladder cancer has the characteristics of having both a high malignancy rate and easy recurrence rate after operation. These factors listed above lead to poor therapeutic effects for bladder cancer patients. Accordingly, early diagnosis and treatment could play an important role in improving the prognosis of patients. Nowadays, with the development of precision medicine and progress being made on new diagnostic and therapeutic technologies, people’s understanding of bladder cancer and the concept of its diagnosis and treatment need to be further deepened, promoting the birth of this book.

This book is divided into six parts including “Precision Medicine for Individualized Therapy”, "Novel Advances in Surgical Technology”, "Debates and Experience in Traditional Surgical Treatment”, "Progress in Chemotherapy and Medical Treatment”, "Fresh Vision of Pathogenesis, Development and Prognosis”, and "Experience and Exploration in Clinical Nursing”. Around these topics, we gathered technical summaries and the experiences from the worldwide leading researchers and clinicians in the field of bladder cancer. It includes not only the recognition and experience summaries of the traditional technology, but it also details the relevant views and opinions on the latest progress made on the diagnosis and treatment process, such as comments on precision medicine, individualized therapies and using big data analysis methods. Through this way, we hope readers can be inspired in their own clinical work and scientific research.

Since ancient times, doctors’ perception of disease has made great progress. However, due to the limitations of the science and technology level in a particular era, the new discoveries will likely to be negated by newer more modern developments in the future. For example, the supposed correct way of diagnosis and treatment in the past, might be gradually abandoned through newer explorations and practices. For another instance, precision medicine and individualized treatments bring newer hopes to the treatment of bladder cancer, It could accurately find the cause and treatment targets for bladder cancer; thus, breaking through the difficulty of the traditional diagnosis and treatment methods. Therefore, the knowledge that we can gain from a disease is infinite, and the pursuit of truth is endless. Only by constantly exploring can we break through the limitations of cognitive space-time, so as to enhance our perceptions to become closer and closer to the objective truth. Only in this way, can we make the right choice and do the right thing for patients as far as possible.

I hoped the publication of this book will contribute to the improvement of readers’ understanding of the diagnosis and treatment of bladder cancer.
Xiao Li, MD
Department of Urologic Surgery,
Jiangsu Cancer Hospital
& Jiangsu Institute of Cancer Research
& Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing, China

Qing Zou, MD
Department of Urologic Surgery,
Jiangsu Cancer Hospital
& Jiangsu Institute of Cancer Research
& Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing, China